- Defence Therapeutics (DTC) is preparing to initiate a phase I trial against melanoma using its DC cancer vaccine candidate AccuVAC-D002
- Defence has developed several cancer vaccine candidates including AccuVAC-D002
- Defence is most likely to initiate its Phase I trials in Q1/Q2 of 2022
- The skin cancer treatment market is expected to reach US$14.55 billion by 2027
- Defence Therapeutics is a biotechnology company engineering next-generation vaccines and ADC products using its proprietary platform
- Defence Therapeutics Inc. (DTC) opened trading at C$6.70 per share
Defence Therapeutics (DTC) is preparing to initiate a phase I trial against melanoma using its DC cancer vaccine candidate AccuVAC-D002.
The AccumTM technology platform is very efficient at enhancing intracellular delivery of proteins of pharmacological interests such as ADCs or vaccine antigens. Defence’s scientific team recently identified a novel function for the use of “free” Accum and its recently developed variants as anti-cancer molecules.
“We have successfully moved our product pipeline forward and developed various cancer vaccines including AccuVAC-D002. With the synopsis in hand, we are actively working with a large established CRO in the USA to identify and set-up the site for our Phase I against melanoma in the first half of 2022,” remarked Mr. Plouffe, CEO of Defence Therapeutics.
Defence Therapeutics has both antibody-drug conjugates and vaccines in late-stage pre-clinical development and/or undergoing GLP studies. With two DC cancer vaccines (AccuVAC-D001 and D002) undergoing manufacturing in clean rooms, Defence is most likely to initiate its Phase I trials in Q1/Q2 of 2022.
The skin cancer treatment market is expected to reach US$14.55 billion by 2027, according to a report by Fortune Business Insights.
Defence Therapeutics is a biotechnology company engineering next-generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.
Defence Therapeutics Inc. (DTC) opened trading at C$6.70 per share.
